Novo invests heavily in Danish manufacturing
Novo Nordisk is now investing DKK 380 million (USD 67 million) in an overhaul of its manufacturing facilities in its factory in the Danish town Kalundborg, in order to produce a new type II diabetes drug, semaglutid, the company reveals.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.